<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576420</url>
  </required_header>
  <id_info>
    <org_study_id>550602</org_study_id>
    <nct_id>NCT00576420</nct_id>
  </id_info>
  <brief_title>Fibrin Sealant Vascular Surgery Study</brief_title>
  <official_title>Clinical Evaluation of Efficacy and Safety of FS VH S/D 500 S-apr for Hemostasis in Subjects Undergoing Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Fibrin Sealant, Vapor
      Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D
      500 s-apr) for hemostasis in participants receiving prosthetic expanded
      polytetrafluoroethylene (ePTFE) conduits as compared to a control group treated by manual
      compression with surgical gauze pads.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line.</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90% Confidence Interval for the Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Suture Line</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment other than study treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</measure>
    <time_frame>4 minutes post start of treatment application</time_frame>
    <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Hemostasis at 6 Minutes</measure>
    <time_frame>6 minutes post start of treatment application start</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Hemostasis at 10 Minutes</measure>
    <time_frame>10 minutes post start of treatment application</time_frame>
    <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at the Study Suture Line</measure>
    <time_frame>Intraoperative day 0</time_frame>
    <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Postoperative Rebleeding After Hemostasis at the Study Suture Line</measure>
    <time_frame>Postoperative through day 30 ± 5</time_frame>
    <description>Any rebleeding requiring surgical reexploration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Any Transfusion Requirement</measure>
    <time_frame>Intraoperative (day 0) through day 30 ± 5</time_frame>
    <description>Proportion of participants who required transfusions (i.e., red blood cell (RBC) concentrates, fresh frozen plasma (FFP), and platelets)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Graft Occlusions</measure>
    <time_frame>Day 0 (procedure day) through day 30 ± 5</time_frame>
    <description>Determined clinically and defined as absence of blood flow through the graft.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infections at the Surgical Site</measure>
    <time_frame>Day 0 (procedure day) through day 30 ± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Systolic and Diastolic Blood Pressure - Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
    <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Heart Rate - Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Heart Rate</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
    <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Respiratory Rate - Preoperative Baseline</measure>
    <time_frame>Within 14 days prior to date of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Vital Signs: Respiratory Rate</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
    <description>Percent Change in Respiratory Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Hemoglobin</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Hematocrit</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Erythrocytes</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Platelets</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Values Over Time: International Normalized Ratio (INR)</measure>
    <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)</condition>
  <arm_group>
    <arm_group_label>FS VH S/D 500 s-apr - 60-Seconds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) will be applied to the study suture line, 60-second polymerization time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FS VH S/D 500 s-apr - 120-Seconds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FS VH S/D 500 s-apr will be applied to the study suture line, 120-second polymerization time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group- Manual compression with surgical gauze pads</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of the study-suture line will be manual compression with surgical gauze pads.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FS VH S/D 500 s-apr, 60-seconds polymerization time</intervention_name>
    <description>FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.</description>
    <arm_group_label>FS VH S/D 500 s-apr - 60-Seconds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FS VH S/D 500 s-apr, 120-seconds polymerization time</intervention_name>
    <description>Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.</description>
    <arm_group_label>FS VH S/D 500 s-apr - 120-Seconds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Manual compression with surgical gauze pads</intervention_name>
    <description>Treatment of the study suture line with manual compression with surgical gauze pads.</description>
    <arm_group_label>Control Group- Manual compression with surgical gauze pads</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of all ages

          -  Subject undergoing peripheral vascular surgery, ie, conduit placement with an ePTFE
             graft such as arterio-arterial bypasses [including: axillo-femoral, ilio-femoral,
             femoro-femoral, ilio-popliteal, femoro-popliteal (including below knee), femoro-tibial
             vessel bypass], or arteriovenous dialysis access shunt in the upper or lower
             extremity.

          -  Signed informed consent

        Intraoperative inclusion criterion:

        - Suture line bleeding eligible for study treatment is present after surgical hemostasis
        (i.e., suturing).

        Suture line bleeding eligible for study treatment is defined as: any suture line bleeding
        that would prevent immediate closure of the wound and require treatment of the bleeding
        first, and on a scale of mild, moderate, and severe, the suture line bleeding is assessed
        as moderate or severe. (Moderate is defined as: either more than 25% of the suture line
        bleeds, or at least 5 suture line bleedings are present, if counting of suture line
        bleedings is possible, or one pulsatile suture line bleeding is present. Severe is defined
        as: either more than 50% of the suture line bleeds, or at least 10 suture line bleedings
        present, if counting of suture line bleedings is possible, or more than one pulsatile
        suture line bleedings are present, or at least one spurting suture line bleeding is
        present.)

        Note: Bleedings that can be treated with additional sutures are not appropriate for the
        study. Such anastomoses should receive additional sutures, be re-categorized, and if they
        still comply with the inclusion criteria, be randomized.

        Exclusion Criteria:

          -  Subjects concurrently participating in another clinical study treatment with another
             investigational drug or device within the last 30 days

          -  Other vascular procedures during the same surgical session (stenting and/or
             endarterectomy of the same artery are allowed)

          -  Arterio-arterial bypasses with more than 2 anastomoses (e.g., aorto-bifemoral,
             axillo-bifemoral etc.)

          -  Pregnant or lactating women

          -  Congenital coagulation disorders

          -  Prior kidney transplantation

          -  Heparin-induced thrombocytopenia

          -  Known prior exposure to aprotinin within the last 12 months

          -  Known hypersensitivity to aprotinin or other components of the product

          -  Known severe congenital or acquired immunodeficiency (e.g., HIV infection or long term
             treatment with immunosuppressive drugs)

          -  Prior radiation therapy to the operating field

          -  Severe local inflammation at the operating field.

        Intraoperative exclusion criterion:

          -  Major intraoperative complications that require resuscitation or deviation from the
             planned surgical procedure.

          -  Intraoperative change in planned surgical procedure, which results in subject no
             longer meeting preoperative inclusion and/or exclusion criteria, (e.g. abandonment of
             ePTFE graft placement).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Saha SP, Muluk S, Schenk W 3rd, Burks SG, Grigorian A, Ploder B, Presch I, Pavlova BG, Hantak E. Use of fibrin sealant as a hemostatic agent in expanded polytetrafluoroethylene graft placement surgery. Ann Vasc Surg. 2011 Aug;25(6):813-22. doi: 10.1016/j.avsg.2010.12.016. Epub 2011 Apr 21.</citation>
    <PMID>21514114</PMID>
  </results_reference>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2007</study_first_posted>
  <results_first_submitted>September 13, 2012</results_first_submitted>
  <results_first_submitted_qc>October 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 27, 2012</results_first_posted>
  <disposition_first_submitted>January 13, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 13, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 18, 2010</disposition_first_posted>
  <last_update_submitted>October 26, 2012</last_update_submitted>
  <last_update_submitted_qc>October 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 12 clinical sites in the United States, beginning December 2007. The last participant completed the study in December 2008</recruitment_details>
      <pre_assignment_details>101 participants were enrolled and screened. 26 were screen failures; 1 was excluded due to study issue; and 1 was withdrawn by investigator. Therefore, 73 of the 101 enrolled were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FS VH S/D 500 S-apr - 60 Seconds</title>
          <description>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60 - seconds polymerization time</description>
        </group>
        <group group_id="P2">
          <title>FS VH S/D 500 S-apr - 120 Seconds</title>
          <description>FS VH S/D 500 s-apr, 120 - seconds polymerization time</description>
        </group>
        <group group_id="P3">
          <title>Control Group</title>
          <description>Manual compression with surgical gauze pads.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FS VH S/D 500 S-apr - 60 Seconds</title>
          <description>FS VH S/D 500 s-apr, 60 - seconds polymerization time</description>
        </group>
        <group group_id="B2">
          <title>FS VH S/D 500 S-apr - 120 Seconds</title>
          <description>FS VH S/D 500 s-apr, 120 - seconds polymerization time</description>
        </group>
        <group group_id="B3">
          <title>Control Group</title>
          <description>Manual compression with surgical gauze pads.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.0" spread="12.7" lower_limit="33" upper_limit="85"/>
                    <measurement group_id="B2" value="67.0" spread="14.6" lower_limit="24" upper_limit="84"/>
                    <measurement group_id="B3" value="63.0" spread="14.4" lower_limit="38" upper_limit="86"/>
                    <measurement group_id="B4" value="63" lower_limit="24" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line.</title>
        <description>Hemostasis at the study suture line must be maintained.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr- 60-Seconds</title>
            <description>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line.</title>
          <description>Hemostasis at the study suture line must be maintained.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary Hemostasis Achieved at 4 Minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional Treatment Required for Hemostasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="52.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraoperative Rebleeding After Primary Hemostasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>90% Confidence Interval for the Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Suture Line</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment other than study treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>90% Confidence Interval for the Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Suture Line</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.
Participants were considered treatment failures if they met any of the following conditions:
Did not achieve hemostasis at 4 minutes
Required additional hemostatic treatment other than study treatment during the first 4 minutes of the observation period
Experienced rebleeding after the first 4 minutes of the observation period.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" lower_limit="30.1" upper_limit="62.2"/>
                    <measurement group_id="O2" value="62.5" lower_limit="46.2" upper_limit="78.8"/>
                    <measurement group_id="O3" value="34.8" lower_limit="18.4" upper_limit="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1564</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</title>
        <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Moderate Bleeding</title>
          <description>Investigators were shown videos of bleeding severities to standardize assessments.
Moderate bleeding defined as:
Either &gt;25% of the suture line bleeds, or
≥5 suture line bleedings were present, if counting of suture line bleedings was possible, or
1 pulsatile suture line bleeding was present.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="28.0" upper_limit="72.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="44.3" upper_limit="89.1"/>
                    <measurement group_id="O3" value="38.5" lower_limit="16.3" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Hemostasis at 6 Minutes</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
        <time_frame>6 minutes post start of treatment application start</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Hemostasis at 6 Minutes</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5" lower_limit="45.8" upper_limit="77.2"/>
                    <measurement group_id="O2" value="75.0" lower_limit="60.5" upper_limit="89.5"/>
                    <measurement group_id="O3" value="34.8" lower_limit="18.4" upper_limit="51.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Hemostasis at 10 Minutes</title>
        <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
        <time_frame>10 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Hemostasis at 10 Minutes</title>
          <description>Hemostasis at the study suture line must be maintained until closure of the surgical wound.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4" lower_limit="50.0" upper_limit="80.7"/>
                    <measurement group_id="O2" value="75.0" lower_limit="60.5" upper_limit="89.5"/>
                    <measurement group_id="O3" value="43.5" lower_limit="26.5" upper_limit="60.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.123</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at the Study Suture Line</title>
        <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
        <time_frame>Intraoperative day 0</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Intraoperative Rebleeding After Hemostasis at the Study Suture Line</title>
          <description>Intraoperative rebleeding at the study suture line after occurrence of hemostasis.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="4.3" lower_limit="0.0" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.929</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.228</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Postoperative Rebleeding After Hemostasis at the Study Suture Line</title>
        <description>Any rebleeding requiring surgical reexploration</description>
        <time_frame>Postoperative through day 30 ± 5</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization.</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Postoperative Rebleeding After Hemostasis at the Study Suture Line</title>
          <description>Any rebleeding requiring surgical reexploration</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Any Transfusion Requirement</title>
        <description>Proportion of participants who required transfusions (i.e., red blood cell (RBC) concentrates, fresh frozen plasma (FFP), and platelets)</description>
        <time_frame>Intraoperative (day 0) through day 30 ± 5</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Transfusion Requirement</title>
          <description>Proportion of participants who required transfusions (i.e., red blood cell (RBC) concentrates, fresh frozen plasma (FFP), and platelets)</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="1.4" upper_limit="23.6"/>
                    <measurement group_id="O3" value="13.0" lower_limit="1.5" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.234</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.955</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Graft Occlusions</title>
        <description>Determined clinically and defined as absence of blood flow through the graft.</description>
        <time_frame>Day 0 (procedure day) through day 30 ± 5</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-Seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr - All - (60 + 120 Seconds)</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Graft Occlusions</title>
          <description>Determined clinically and defined as absence of blood flow through the graft.</description>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="0.0" upper_limit="16.3"/>
                    <measurement group_id="O2" value="4.2" lower_limit="0.0" upper_limit="10.9"/>
                    <measurement group_id="O3" value="6.0" lower_limit="0.5" upper_limit="11.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.106</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Infections at the Surgical Site</title>
        <time_frame>Day 0 (procedure day) through day 30 ± 5</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr All - (60 + 120 Seconds)</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Infections at the Surgical Site</title>
          <population>Safety Analysis Set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="0.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="8.3" lower_limit="0.0" upper_limit="17.6"/>
                    <measurement group_id="O3" value="6.0" lower_limit="0.5" upper_limit="11.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.257</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.127</p_value>
            <method>Likelihood ratio chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Systolic and Diastolic Blood Pressure - Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S -Apr - 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization (FS 60)</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S -Apr - 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization (FS 120)</description>
          </group>
          <group group_id="O3">
            <title>FS VH S/D 500 S-apr - All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds polymerization time) (FS All):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Systolic and Diastolic Blood Pressure - Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>mm Hg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.5" lower_limit="95.0" upper_limit="182.0"/>
                    <measurement group_id="O2" value="142.5" lower_limit="96.0" upper_limit="208.0"/>
                    <measurement group_id="O3" value="141.5" lower_limit="95.0" upper_limit="208.0"/>
                    <measurement group_id="O4" value="150.0" lower_limit="91.0" upper_limit="194.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="46.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="73.5" lower_limit="54.0" upper_limit="137.0"/>
                    <measurement group_id="O3" value="72.0" lower_limit="46.0" upper_limit="137.0"/>
                    <measurement group_id="O4" value="78.0" lower_limit="48.0" upper_limit="111.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</title>
        <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline – Intraoperative Day 0; Preoperative Baseline – Postoperative Day 1; and Preoperative Baseline – Postoperative Day 14</description>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr (FS), 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline - Intraoperative Day 0</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline - Intraoperative Day 0</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Preoperative Baseline - Postoperative Day 1</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Preoperative Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O9">
            <title>FS 60: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O10">
            <title>FS 120: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O11">
            <title>FS All: Preoperative Baseline - Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O12">
            <title>Control Group: Preoperative Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Systolic and Diastolic Blood Pressure</title>
          <description>Percent Change in Systolic and Diastolic Blood Pressure (BP) Measured as: Preoperative Baseline – Intraoperative Day 0; Preoperative Baseline – Postoperative Day 1; and Preoperative Baseline – Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.1" lower_limit="-36.8" upper_limit="21.4"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-42.2" upper_limit="44.4"/>
                    <measurement group_id="O3" value="-9.8" lower_limit="-42.2" upper_limit="44.4"/>
                    <measurement group_id="O4" value="-17.2" lower_limit="-51.5" upper_limit="15.4"/>
                    <measurement group_id="O5" value="-6.4" lower_limit="-34.7" upper_limit="54.1"/>
                    <measurement group_id="O6" value="-12.4" lower_limit="-47.1" upper_limit="62.5"/>
                    <measurement group_id="O7" value="-7.9" lower_limit="-47.1" upper_limit="62.5"/>
                    <measurement group_id="O8" value="-11.0" lower_limit="-29.5" upper_limit="44.4"/>
                    <measurement group_id="O9" value="-3.8" lower_limit="-29.7" upper_limit="46.9"/>
                    <measurement group_id="O10" value="-3.7" lower_limit="-47.1" upper_limit="50.9"/>
                    <measurement group_id="O11" value="-3.8" lower_limit="-47.1" upper_limit="50.9"/>
                    <measurement group_id="O12" value="-6.6" lower_limit="-33.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" lower_limit="-66.7" upper_limit="100.0"/>
                    <measurement group_id="O2" value="-16.4" lower_limit="-64.6" upper_limit="36.5"/>
                    <measurement group_id="O3" value="-11.4" lower_limit="-66.7" upper_limit="100.0"/>
                    <measurement group_id="O4" value="-21.9" lower_limit="-45.0" upper_limit="41.7"/>
                    <measurement group_id="O5" value="-1.5" lower_limit="-38.5" upper_limit="63.0"/>
                    <measurement group_id="O6" value="-19.4" lower_limit="-60.6" upper_limit="40.0"/>
                    <measurement group_id="O7" value="-7.5" lower_limit="-60.6" upper_limit="63.0"/>
                    <measurement group_id="O8" value="-9.6" lower_limit="-39.4" upper_limit="13.8"/>
                    <measurement group_id="O9" value="0.0" lower_limit="-28.6" upper_limit="36.7"/>
                    <measurement group_id="O10" value="-7.5" lower_limit="-48.9" upper_limit="51.9"/>
                    <measurement group_id="O11" value="-1.1" lower_limit="-48.9" upper_limit="51.9"/>
                    <measurement group_id="O12" value="-7.1" lower_limit="-37.5" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Heart Rate - Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds polymerization time):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Heart Rate - Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>Heart beats/ minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="50.0" upper_limit="139.0"/>
                    <measurement group_id="O2" value="71.5" lower_limit="53.0" upper_limit="98.0"/>
                    <measurement group_id="O3" value="72.0" lower_limit="50.0" upper_limit="139.0"/>
                    <measurement group_id="O4" value="74.0" lower_limit="57.0" upper_limit="112.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Heart Rate</title>
        <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline - Intraoperative Day 0</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline - Intraoperative Day 0</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline - Intraoperative Day 0</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Preoperative Baseline - Postoperative Day 1</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Preoperative Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O9">
            <title>FS 60: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O10">
            <title>FS 120: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O11">
            <title>FS All: Preoperative Baseline - Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O12">
            <title>Control Group: Preoperative Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Heart Rate</title>
          <description>Percent Change in Heart Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="23"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="50"/>
                <count group_id="O8" value="23"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="22"/>
                <count group_id="O11" value="47"/>
                <count group_id="O12" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-58.3" upper_limit="38.6"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-35.6" upper_limit="37.1"/>
                    <measurement group_id="O3" value="-6.3" lower_limit="-58.3" upper_limit="38.6"/>
                    <measurement group_id="O4" value="-9.5" lower_limit="-30.8" upper_limit="21.2"/>
                    <measurement group_id="O5" value="-6.7" lower_limit="-34.0" upper_limit="27.1"/>
                    <measurement group_id="O6" value="2.0" lower_limit="-30.6" upper_limit="32.7"/>
                    <measurement group_id="O7" value="-1.4" lower_limit="-34.0" upper_limit="32.7"/>
                    <measurement group_id="O8" value="9.9" lower_limit="-24.4" upper_limit="54.5"/>
                    <measurement group_id="O9" value="3.0" lower_limit="-19.5" upper_limit="30.6"/>
                    <measurement group_id="O10" value="7.4" lower_limit="-30.1" upper_limit="22.9"/>
                    <measurement group_id="O11" value="4.4" lower_limit="-30.1" upper_limit="30.6"/>
                    <measurement group_id="O12" value="1.8" lower_limit="-26.8" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Respiratory Rate - Preoperative Baseline</title>
        <time_frame>Within 14 days prior to date of surgery</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds polymerization time):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Respiratory Rate - Preoperative Baseline</title>
          <population>Safety Analysis Set</population>
          <units>Breaths/ minute</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="15.0" upper_limit="24.0"/>
                    <measurement group_id="O2" value="20.0" lower_limit="13.0" upper_limit="20.0"/>
                    <measurement group_id="O3" value="18.0" lower_limit="13.0" upper_limit="24.0"/>
                    <measurement group_id="O4" value="18.0" lower_limit="16.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Vital Signs: Respiratory Rate</title>
        <description>Percent Change in Respiratory Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline - Postoperative Day 1</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline - Postoperative Day 1</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline - Postoperative Day 1</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Preoperative Baseline - Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Preoperative Baseline - Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Preoperative Baseline - Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Vital Signs: Respiratory Rate</title>
          <description>Percent Change in Respiratory Rate Measured as: Preoperative Baseline - Intraoperative Day 0; Preoperative Baseline - Postoperative Day 1; and Preoperative Baseline - Postoperative Day 14</description>
          <population>Safety Analysis Set</population>
          <units>percent change</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="21"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="43"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-35.0" upper_limit="33.3"/>
                    <measurement group_id="O2" value="-10.0" lower_limit="-30.0" upper_limit="28.6"/>
                    <measurement group_id="O3" value="-10.0" lower_limit="-35.0" upper_limit="33.3"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-23.1" upper_limit="25.0"/>
                    <measurement group_id="O5" value="0.0" lower_limit="-20.0" upper_limit="25.0"/>
                    <measurement group_id="O6" value="0.0" lower_limit="-29.4" upper_limit="38.5"/>
                    <measurement group_id="O7" value="0.0" lower_limit="-29.4" upper_limit="38.5"/>
                    <measurement group_id="O8" value="0.0" lower_limit="-46.2" upper_limit="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Hemoglobin</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Hemoglobin</title>
          <population>Safety Analysis Set</population>
          <units>g/dl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" lower_limit="6.60" upper_limit="16.50"/>
                    <measurement group_id="O2" value="12.55" lower_limit="9.00" upper_limit="16.60"/>
                    <measurement group_id="O3" value="12.25" lower_limit="6.60" upper_limit="16.60"/>
                    <measurement group_id="O4" value="12.15" lower_limit="10.10" upper_limit="14.70"/>
                    <measurement group_id="O5" value="11.15" lower_limit="7.60" upper_limit="16.10"/>
                    <measurement group_id="O6" value="12.40" lower_limit="8.30" upper_limit="14.40"/>
                    <measurement group_id="O7" value="12.05" lower_limit="7.60" upper_limit="16.10"/>
                    <measurement group_id="O8" value="11.70" lower_limit="8.50" upper_limit="13.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Hematocrit</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Hematocrit</title>
          <population>Safety Analysis Set</population>
          <units>percentage of red blood cells in blood</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.00" lower_limit="23.00" upper_limit="47.00"/>
                    <measurement group_id="O2" value="37.00" lower_limit="30.00" upper_limit="51.00"/>
                    <measurement group_id="O3" value="37.00" lower_limit="23.00" upper_limit="51.00"/>
                    <measurement group_id="O4" value="39.00" lower_limit="30.00" upper_limit="45.00"/>
                    <measurement group_id="O5" value="35.00" lower_limit="26.00" upper_limit="48.00"/>
                    <measurement group_id="O6" value="38.00" lower_limit="28.00" upper_limit="47.00"/>
                    <measurement group_id="O7" value="37.00" lower_limit="26.00" upper_limit="48.00"/>
                    <measurement group_id="O8" value="36.50" lower_limit="27.00" upper_limit="41.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Erythrocytes</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Erythrocytes</title>
          <population>Safety Analysis Set</population>
          <units>x10^6/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.10" lower_limit="3.10" upper_limit="5.30"/>
                    <measurement group_id="O2" value="4.15" lower_limit="3.10" upper_limit="5.30"/>
                    <measurement group_id="O3" value="4.10" lower_limit="3.10" upper_limit="5.30"/>
                    <measurement group_id="O4" value="4.40" lower_limit="3.30" upper_limit="5.00"/>
                    <measurement group_id="O5" value="3.75" lower_limit="2.90" upper_limit="5.40"/>
                    <measurement group_id="O6" value="4.15" lower_limit="2.80" upper_limit="5.80"/>
                    <measurement group_id="O7" value="3.90" lower_limit="2.80" upper_limit="5.80"/>
                    <measurement group_id="O8" value="4.00" lower_limit="2.90" upper_limit="4.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Leukocytes, Basophils, Eosinophils, Lymphocytes, Neutrophils, and Monocytes</title>
          <population>Safety Analysis Set</population>
          <units>x10^3/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="46"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Leukocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" lower_limit="2.48" upper_limit="16.22"/>
                    <measurement group_id="O2" value="7.14" lower_limit="3.45" upper_limit="15.16"/>
                    <measurement group_id="O3" value="6.62" lower_limit="2.48" upper_limit="16.22"/>
                    <measurement group_id="O4" value="7.98" lower_limit="3.62" upper_limit="13.76"/>
                    <measurement group_id="O5" value="6.58" lower_limit="3.34" upper_limit="14.12"/>
                    <measurement group_id="O6" value="7.87" lower_limit="4.36" upper_limit="16.89"/>
                    <measurement group_id="O7" value="7.00" lower_limit="3.34" upper_limit="16.89"/>
                    <measurement group_id="O8" value="8.13" lower_limit="6.25" upper_limit="18.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.00" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.00" upper_limit="0.10"/>
                    <measurement group_id="O3" value="0.05" lower_limit="0.00" upper_limit="0.12"/>
                    <measurement group_id="O4" value="0.04" lower_limit="0.00" upper_limit="0.10"/>
                    <measurement group_id="O5" value="0.04" lower_limit="0.00" upper_limit="0.19"/>
                    <measurement group_id="O6" value="0.05" lower_limit="0.02" upper_limit="0.23"/>
                    <measurement group_id="O7" value="0.05" lower_limit="0.00" upper_limit="0.23"/>
                    <measurement group_id="O8" value="0.04" lower_limit="0.00" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="0.02" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.02" upper_limit="0.96"/>
                    <measurement group_id="O3" value="0.15" lower_limit="0.02" upper_limit="0.96"/>
                    <measurement group_id="O4" value="0.19" lower_limit="0.04" upper_limit="0.83"/>
                    <measurement group_id="O5" value="0.21" lower_limit="0.02" upper_limit="0.96"/>
                    <measurement group_id="O6" value="0.24" lower_limit="0.01" upper_limit="0.52"/>
                    <measurement group_id="O7" value="0.23" lower_limit="0.01" upper_limit="0.96"/>
                    <measurement group_id="O8" value="0.21" lower_limit="0.08" upper_limit="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="0.57" upper_limit="3.86"/>
                    <measurement group_id="O2" value="1.74" lower_limit="0.56" upper_limit="3.10"/>
                    <measurement group_id="O3" value="1.55" lower_limit="0.56" upper_limit="3.86"/>
                    <measurement group_id="O4" value="1.59" lower_limit="1.09" upper_limit="4.26"/>
                    <measurement group_id="O5" value="1.50" lower_limit="0.60" upper_limit="4.59"/>
                    <measurement group_id="O6" value="1.46" lower_limit="0.51" upper_limit="3.11"/>
                    <measurement group_id="O7" value="1.48" lower_limit="0.51" upper_limit="4.59"/>
                    <measurement group_id="O8" value="1.94" lower_limit="0.86" upper_limit="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.70" lower_limit="1.59" upper_limit="12.55"/>
                    <measurement group_id="O2" value="4.69" lower_limit="2.22" upper_limit="13.70"/>
                    <measurement group_id="O3" value="4.11" lower_limit="1.59" upper_limit="13.70"/>
                    <measurement group_id="O4" value="5.24" lower_limit="2.17" upper_limit="8.67"/>
                    <measurement group_id="O5" value="4.44" lower_limit="2.38" upper_limit="9.92"/>
                    <measurement group_id="O6" value="5.23" lower_limit="2.72" upper_limit="15.38"/>
                    <measurement group_id="O7" value="4.66" lower_limit="2.38" upper_limit="15.38"/>
                    <measurement group_id="O8" value="5.54" lower_limit="3.81" upper_limit="14.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" lower_limit="0.08" upper_limit="0.72"/>
                    <measurement group_id="O2" value="0.41" lower_limit="0.20" upper_limit="0.82"/>
                    <measurement group_id="O3" value="0.36" lower_limit="0.08" upper_limit="0.82"/>
                    <measurement group_id="O4" value="0.39" lower_limit="0.18" upper_limit="0.83"/>
                    <measurement group_id="O5" value="0.35" lower_limit="0.22" upper_limit="0.58"/>
                    <measurement group_id="O6" value="0.43" lower_limit="0.22" upper_limit="0.77"/>
                    <measurement group_id="O7" value="0.38" lower_limit="0.22" upper_limit="0.77"/>
                    <measurement group_id="O8" value="0.44" lower_limit="0.13" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Platelets</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Platelets</title>
          <population>Safety Analysis Set</population>
          <units>x10^3/µl</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.00" lower_limit="70.00" upper_limit="423.00"/>
                    <measurement group_id="O2" value="204.00" lower_limit="56.00" upper_limit="442.00"/>
                    <measurement group_id="O3" value="195.50" lower_limit="56.00" upper_limit="442.00"/>
                    <measurement group_id="O4" value="233.00" lower_limit="132.00" upper_limit="462.00"/>
                    <measurement group_id="O5" value="226.00" lower_limit="138.00" upper_limit="538.00"/>
                    <measurement group_id="O6" value="333.00" lower_limit="117.00" upper_limit="593.00"/>
                    <measurement group_id="O7" value="275.00" lower_limit="117.00" upper_limit="593.00"/>
                    <measurement group_id="O8" value="295.00" lower_limit="199.00" upper_limit="386.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Creatinine, Bilirubin, and Blood Urea Nitrogen (BUN)</title>
          <population>Safety Analysis Set</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.20" lower_limit="0.50" upper_limit="13.80"/>
                    <measurement group_id="O2" value="1.90" lower_limit="0.60" upper_limit="13.30"/>
                    <measurement group_id="O3" value="3.50" lower_limit="0.50" upper_limit="13.80"/>
                    <measurement group_id="O4" value="2.65" lower_limit="0.50" upper_limit="9.40"/>
                    <measurement group_id="O5" value="4.60" lower_limit="0.60" upper_limit="12.70"/>
                    <measurement group_id="O6" value="2.40" lower_limit="0.60" upper_limit="12.70"/>
                    <measurement group_id="O7" value="3.50" lower_limit="0.60" upper_limit="12.70"/>
                    <measurement group_id="O8" value="3.25" lower_limit="0.50" upper_limit="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" lower_limit="0.20" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.20" upper_limit="1.10"/>
                    <measurement group_id="O3" value="0.30" lower_limit="0.20" upper_limit="1.10"/>
                    <measurement group_id="O4" value="0.40" lower_limit="0.20" upper_limit="0.70"/>
                    <measurement group_id="O5" value="0.30" lower_limit="0.20" upper_limit="3.30"/>
                    <measurement group_id="O6" value="0.40" lower_limit="0.20" upper_limit="0.70"/>
                    <measurement group_id="O7" value="0.30" lower_limit="0.20" upper_limit="3.30"/>
                    <measurement group_id="O8" value="0.30" lower_limit="0.20" upper_limit="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BUN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.00" lower_limit="6.00" upper_limit="104.00"/>
                    <measurement group_id="O2" value="31.00" lower_limit="8.00" upper_limit="122.00"/>
                    <measurement group_id="O3" value="26.00" lower_limit="6.00" upper_limit="122.00"/>
                    <measurement group_id="O4" value="29.00" lower_limit="9.00" upper_limit="73.00"/>
                    <measurement group_id="O5" value="30.00" lower_limit="4.00" upper_limit="72.00"/>
                    <measurement group_id="O6" value="26.00" lower_limit="8.00" upper_limit="125.00"/>
                    <measurement group_id="O7" value="27.00" lower_limit="4.00" upper_limit="125.00"/>
                    <measurement group_id="O8" value="27.00" lower_limit="6.00" upper_limit="84.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Alanine Aminotransferase (ALT)</title>
          <population>Safety Analysis Set</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="48"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="47"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.00" lower_limit="4.00" upper_limit="47.00"/>
                    <measurement group_id="O2" value="17.00" lower_limit="7.00" upper_limit="43.00"/>
                    <measurement group_id="O3" value="16.00" lower_limit="4.00" upper_limit="47.00"/>
                    <measurement group_id="O4" value="16.50" lower_limit="7.00" upper_limit="29.00"/>
                    <measurement group_id="O5" value="12.00" lower_limit="4.00" upper_limit="32.00"/>
                    <measurement group_id="O6" value="15.00" lower_limit="4.00" upper_limit="39.00"/>
                    <measurement group_id="O7" value="14.00" lower_limit="4.00" upper_limit="39.00"/>
                    <measurement group_id="O8" value="12.00" lower_limit="4.00" upper_limit="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Aspartate Aminotransferase (AST)</title>
          <population>Safety Analysis Set</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="19"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.00" lower_limit="14.00" upper_limit="51.00"/>
                    <measurement group_id="O2" value="19.00" lower_limit="11.00" upper_limit="45.00"/>
                    <measurement group_id="O3" value="18.00" lower_limit="11.00" upper_limit="51.00"/>
                    <measurement group_id="O4" value="16.00" lower_limit="12.00" upper_limit="44.00"/>
                    <measurement group_id="O5" value="18.00" lower_limit="13.00" upper_limit="29.00"/>
                    <measurement group_id="O6" value="20.00" lower_limit="7.00" upper_limit="39.00"/>
                    <measurement group_id="O7" value="19.00" lower_limit="7.00" upper_limit="39.00"/>
                    <measurement group_id="O8" value="17.50" lower_limit="11.00" upper_limit="30.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: Activated Partial Thromboplastin Time (aPTT)</title>
          <population>Safety Analysis Set</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="18"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.10" lower_limit="19.60" upper_limit="109.80"/>
                    <measurement group_id="O2" value="26.30" lower_limit="21.60" upper_limit="51.00"/>
                    <measurement group_id="O3" value="25.90" lower_limit="19.60" upper_limit="109.80"/>
                    <measurement group_id="O4" value="25.10" lower_limit="19.90" upper_limit="150.00"/>
                    <measurement group_id="O5" value="24.65" lower_limit="20.30" upper_limit="150.00"/>
                    <measurement group_id="O6" value="27.20" lower_limit="20.10" upper_limit="150.00"/>
                    <measurement group_id="O7" value="25.00" lower_limit="20.10" upper_limit="150.00"/>
                    <measurement group_id="O8" value="26.75" lower_limit="20.40" upper_limit="150.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Values Over Time: International Normalized Ratio (INR)</title>
        <time_frame>Preoperative baseline through postoperative Day 14</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FS 60: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O2">
            <title>FS 120: Preoperative Baseline</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O3">
            <title>FS All: Preoperative Baseline</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O4">
            <title>Control Group: Preoperative Baseline</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
          <group group_id="O5">
            <title>FS 60: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization</description>
          </group>
          <group group_id="O6">
            <title>FS 120: Postoperative Day 14</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization</description>
          </group>
          <group group_id="O7">
            <title>FS All: Postoperative Day 14</title>
            <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60-seconds polymerization time
FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O8">
            <title>Control Group: Postoperative Day 14</title>
            <description>Manual compression with surgical gauze pads</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory Values Over Time: International Normalized Ratio (INR)</title>
          <population>Safety Analysis Set</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="24"/>
                <count group_id="O6" value="17"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.90" upper_limit="1.20"/>
                    <measurement group_id="O2" value="1.10" lower_limit="1.00" upper_limit="2.40"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.90" upper_limit="2.40"/>
                    <measurement group_id="O4" value="1.05" lower_limit="0.90" upper_limit="1.20"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.90" upper_limit="2.10"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.90" upper_limit="3.20"/>
                    <measurement group_id="O7" value="1.00" lower_limit="0.90" upper_limit="3.20"/>
                    <measurement group_id="O8" value="1.00" lower_limit="0.90" upper_limit="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</title>
        <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
        <time_frame>4 minutes post start of treatment application</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>FS VH S/D 500 S-apr - 60-Seconds</title>
            <description>FS VH S/D 500 s-apr, 60-seconds polymerization time</description>
          </group>
          <group group_id="O2">
            <title>FS VH S/D 500 S-apr - 120-Seconds</title>
            <description>FS VH S/D 500 s-apr, 120-seconds polymerization time</description>
          </group>
          <group group_id="O3">
            <title>Control Group</title>
            <description>Manual compression with surgical gauze pads.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemostasis at 4 Minutes After Treatment Application at the Suture Line by Bleeding Severity - Severe Bleeding</title>
          <description>Investigators were shown videos of bleeding severities to standardize assessments.
Severe bleeding defined as:
Either &gt;50% of the suture line bleeds, or
≥10 suture line bleedings were present, if counting of suture line bleedings was possible, or
&gt;1 pulsatile suture line bleeding was present, or
≥1 spurting suture line bleeding was present.</description>
          <population>Intent to Treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="18.3" upper_limit="65.1"/>
                    <measurement group_id="O2" value="58.3" lower_limit="34.9" upper_limit="81.7"/>
                    <measurement group_id="O3" value="30.0" lower_limit="6.2" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout study period (1 year)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fibrin Sealant - 60 Seconds</title>
          <description>Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60 seconds polymerization time</description>
        </group>
        <group group_id="E2">
          <title>Fibrin Sealant - 120 Seconds</title>
          <description>FS VH S/D 500 s-apr, 120 seconds polymerization time</description>
        </group>
        <group group_id="E3">
          <title>Fibrin Sealant All - (60 + 120 Seconds)</title>
          <description>All study participants who received Fibrin Sealant (60 + 120 Seconds):
Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), 60 seconds polymerization time
FS VH S/D 500 s-apr, 120 seconds polymerization time</description>
        </group>
        <group group_id="E4">
          <title>Control Group</title>
          <description>Treatment of the study-suture line will be manual compression with surgical gauze pads.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Incision site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vascular graft complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incision site complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Incision site oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Incision site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter's agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 1 year after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥45 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., for intellectual property protection)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edith Hantak, Dir, Global Therapeutic Area, BioSurgery</name_or_title>
      <organization>BAXTER INNOVATIONS GmbH</organization>
      <email>edith_hantak@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

